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Abstract
Aims/hypothesis Effects of the transcription factor v-maf
musculoaponeurotic fibrosarcoma oncogene homologue A
(MAFA) on the regulation of beta cell gene expression and
function were investigated.
Materials and methods INS-1 stable cell lines permitting
inducible up- or downregulation of this transcription factor
were established.
Results MAFA overproduction enhanced and its dominant-
negative mutant (DN-MAFA) diminished binding of the
factor to the insulin promoter, correlating with insulin
mRNA levels and cellular protein content. Glucose-stimu-
lated insulin secretion was facilitated by MAFA and
blunted by DN-MAFA. This is partly due to alterations in
glucokinase production, the glucose sensor of beta cells. In
addition, the expression of important beta cell genes, e.g.
those encoding solute carrier family 2 (facilitated glucose
transporter), member 2 (formerly known as GLUT2),
pancreatic and duodenal homeobox factor 1 (PDX1), NK6
transcription factor-related, locus 1 (NKX6-1), glucagon-
like peptide 1 receptor (GLP1R), prohormone convertase
1/3 (PCSK1) and pyruvate carboxylase (PC), was regulated
positively by MAFA and negatively by DN-MAFA.
Conclusions/interpretation The data suggest that MAFA is
not only a key activator of insulin transcription, but also a
master regulator of genes implicated in maintaining beta
cell function, in particular metabolism–secretion coupling,
proinsulin processing and GLP1R signalling. Our in vitro
study provides molecular targets that explain the phenotype
of recently reported Mafa-null mice. We also demonstrate
that MAFA is produced specifically in beta cells of human
islets. Glucose influenced DNA-binding activity of MAFA
in rat islets in a bell-shaped manner. MAFA thus qualifies
as a master regulator of beta-cell-specific gene expression
and function.
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Abbreviations
DN-MAFA dominant-negative mutant of MAFA
EMSA electrophoretic mobility-shift assay
GCK glucokinase
GLP1R glucagon-like peptide 1 receptor
HADH2 3-hydroxyacyl-CoA dehydrogenase type II
HNF4α hepatocyte nuclear factor 4 α
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ISL1 ISL1 transcription factor LIM/homeodomain
(islet-1)
KRBH KRB-HEPES buffer
MAFA v-maf musculoponeurotic fibrosarcoma
oncogene homologue A
NEUROD1 neurogenic differentiation factor 1
NKX6-1 NK6 transcription factor-related, locus 1
PAX4 paired-box protein 4
PC pyruvate carboxylase
PCSK1 prohormone convertase 1/3
PDX1 pancreatic and duodenal homeobox factor 1
SLC2A2 solute carrier family 2 (facilitated glucose
transporter), member 2
TCF1 transcription factor 1, hepatic
TFAM transcription factor A, mitochondrial
UCP2 uncoupling protein 2 (mitochondrial, proton
carrier)
Introduction
Type 1 diabetes is characterised by absolute insulin deficiency
caused by autoimmune destruction of the insulin-producing
pancreatic beta cells. Patients with this disease require daily
injections of insulin or islet transplantation. Because islet
donors are scarce, the generation of insulin-producing cells
from human progenitor/stem cells has become a key challenge
in the treatment of type 1 diabetes. The reduction in insulin
secretory capacity and beta cell mass are the precipitating
factors for development of type 2 diabetes in addition to
insulin resistance in the liver, muscle and adipose tissues.
Therefore, the identification and characterisation of key
transcription factors regulating beta cell gene expression and
insulin secretion are essential not only for treatment of type 1
diabetes but also for understanding the pathogenesis of beta
cell dysfunction in type 2 diabetes.
The beta cell specificity and glucose responsiveness of
insulin expression are conferred by three conserved
enhancer elements in the promoter region of the insulin
gene. These are E1, A3, and RIPE3b/C1, which, respec-
tively, bind three transcription factors: neurogenic differen-
tiation factor 1 (NEUROD1), pancreatic and duodenal
homeobox factor 1 (also known as insulin promoter factor
1, homeodomain transcription factor [IPF1]) and v-maf
musculoaponeurotic fibrosarcoma oncogene homologue A
(MAFA) [1–5]. NEUROD1 is produced in all pancreatic
endocrine cell types, whereas PDX1 and MAFA display
beta-cell-restricted production [1–5]. Mouse models with
targeted gene disruption have revealed the essential roles of
Neurod1 and Pdx1 in pancreatic development and beta cell
differentiation. In addition, mutations in human NEUROD1
and PDX1 are associated, respectively, with MODY,
subtypes 4 and 6. Moreover, adenovirus vector-mediated
gene therapy using either Neurod1 in combination with
betacellulin [6] or Pdx1 alone [7] has been shown to induce
insulin production in mouse liver and cure streptozotocin-
induced diabetes. Similar gene therapy was recently shown
to yield encouraging results, taking advantage of the
synergistic actions of Mafa, Pdx1 and Neurod1 [8].
Furthermore, beta cell replacement therapy in similar
animal models has been achieved using in vitro-differenti-
ated insulin-producing cells, which are generated through
expression of Pdx1 in human fetal liver progenitor cells [9].
Large MAF proteins represent a subgroup of the MAF
family of basic-leucine zipper transcription factors and
include MAFA, c-MAF, MAFB and neural retina-specific
leucine zipper protein (NRL) [4, 5]. MAFA is a key
regulator of insulin gene transcription, whereas c-MAF and
MAFB are produced specifically in adult alpha cells and
control the glucagon promoter activity [4, 10]. Recent
studies, however, suggest that MAFB is not only important
for islet alpha cell function, but may also be involved in
regulating genes required for both alpha and beta cell
differentiation during development [11–13]. It is noteworthy
that reduced MAFA function has been implicated in the
development of beta cell dysfunction [14–19]. Hyper-
glycaemia suppresses Mafa expression in vivo, which is
prevented by constitutive overexpression of forkhead box
O1 (Foxo1) in beta cells [14]. In addition, glucotoxicity and
lipotoxicity inhibit insulin expression through regulation of
the DNA-binding activity and/or levels of MAFA and
PDX1 [18]. Moreover, reduced expression of Mafa has
been reported in beta cells deficient in both insulin and
IGF-1 receptors and is associated with reduced beta cell
mass and diabetes [19].
The role of MAFA in regulation of pancreatic beta cell
gene expression and insulin secretion has not been fully
characterised. Using inducible INS-1 beta cell models, we
have previously defined the function of PDX1 in the
regulation of target gene expression and insulin secretion
[20, 21], consistent with the results obtained in mice with
beta-cell-specific deletion of Pdx1 [22, 23]. Similar
approaches were employed in the present study to establish
the regulatory role of MAFA in beta cell function.
Materials and methods
Establishment of inducible INS-1 stable cell lines The first-
step stable and INS-1-derived INS-rbeta (also referred to as
r9) cell line, which carries the reverse tetracycline/doxycy-
cline-dependent transactivator [24] has been described
previously [20, 25]. The plasmids used in the secondary
stable transfection were constructed by subcloning the
cDNA encoding either wild-type MAFA [5] or its domi-
nant-negative mutant (DN-MAFA) [3] into the expression
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vector PUHD10-3 [24] (a generous gift from H. Bujard,
University of Heidelberg, Germany). Both MAFA and DN-
MAFA were epitope-tagged with haemagglutinin. The
procedures for stable transfection, clone selection, and
screening have been described previously [25].
Cell culture The standard rat insulinoma INS-1-derived
stable cell lines were cultured in RPMI 1640 containing
11.2 mmol/l glucose [26], unless otherwise indicated.
Immunofluorescence in INS-1 cells Cells grown on poly-
ornithine-treated glass coverslips were treated for 24 h with
or without 500 ng/ml doxycycline. Cells were then fixed
and incubated with anti-haemagglutinin tag (a kind gift
from MBL/LabForce, Nunningen, Switzerland) (1:100
dilution), followed by the second antibody labelling.
Nuclear protein extraction and electrophoretic mobility-shift
assay Nuclear extracts from INS-1 cells were prepared as
previously described [26]. Rat islets were isolated by
collagenase digestion and their nuclear proteins were
extracted as reported [26]. The double-stranded oligonucle-
otide corresponding to the RIPE3b/C1 element of the rat
insul in II promoter, 5 ′-TGGAAACTGCAGCTT
CAGCCCCTCTG-3′, was used as a probe [4]. Electropho-
retic mobility-shift assay (EMSA) procedures were per-
formed using the same conditions for probe labelling and
binding reactions as previously described [26]. Anti-MAFA
antibody (Bethyl, Montgomery, TX, USA) was used for
supershift experiments.
Western blotting For western blotting, cells were cultured
with 0, 75, 150, and 500 ng/ml doxycycline for 24 h.
Nuclear extracts and total cellular proteins were fractionat-
ed by 11% SDS-PAGE. The dilution for MAFA antibody
was 1:4,000. Immunoblotting procedures were performed
as described previously [26] using enhanced chemilumi-
nescence (Pierce, Rockford, IL, USA) for detection.
Measurements of insulin secretion and cellular insulin
content Insulin secretion in INS-1-derived cells was mea-
sured in 24-well plates over a period of 30 min, in KRB-
HEPES buffer (KRBH; mmol/l: 140 NaCl, 3.6 KCl, 0.5
NaH2PO4, 0.5 MgSO4, 1.5 CaCl2, 2 NaHCO3, 10 HEPES,
0.1% BSA) containing the indicated concentrations of
glucose. Cellular insulin content was determined after
extraction with acid ethanol following the procedures of
Wang et al. [26]. Insulin was detected by radioimmunoas-
say using rat insulin as a standard [26].
Total RNA isolation and northern blotting Total RNA was
extracted and blotted onto nylon membranes as described
previously [25]. The membrane was prehybridised and then
hybridised to 32P-labelled random primer cDNA probes
according to Wang and Iynedijian [25]. To ensure equal
RNA loading and even transfer, all membranes were
stripped and re-hybridised with a house-keeping gene probe
(cyclophilin). cDNA fragments used as probes for Mafa,
glucokinase (Gck), solute carrier family 2 (facilitated
glucose transporter), member 2 (Slc2a2, formerly known
as Glut2), insulin, transcription factor 1, hepatic (Tcf1,
formerly known as hepatocyte nuclear factor 1 α [Hnf1α]),
hepatocyte nuclear factor 4 α (Hnf4a), NeuroD1 and Pdx1
mRNA detection were digested from the corresponding
plasmids. cDNA probes for rat glucagon-like peptide 1
receptor (Glp1r), NK6 transcription factor-related, locus 1
(Nkx6-1), glucagon, prohormone convertase 1/3 (Pcsk1),
pyruvate carboxylase, uncoupling protein 2 (mitochondrial,
proton carrier) (Ucp2), transcription factor A, mitochondrial
(Tfam), short-chain 3-hydroxyacyl-CoA dehydrogenase
Fig. 1 Both MAFA and DN-MAFA were induced in an all-or-none
manner. Immunofluorescence staining with antibody against haemag-
glutinin (HA)-tag showed that both MAFA (a) and DN-MAFA (b)
proteins were induced by doxycycline in an all-or-none manner. The
phase contrast images are shown on the right. HA-Mafa*22 (a) and
HA-DN-Mafa*39 (b) cells were cultured with (+Dox) or without
(−Dox) 500 ng/ml doxycycline for 24 h
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type II (Hadh2), acyl-CoA oxidase and cyclophilin were
prepared by RT-PCR and confirmed by sequencing.
Human islet isolation and culture Freshly isolated human
islets from three different donors, who had provided written
informed consent, were obtained from D. Bosco (Cell
Isolation and Transplantation Center, Department of Sur-
gery, Geneva, Switzerland) and maintained in CMRL-1066
(Invitrogen) at 5.6 mmol/l glucose supplemented with 10%
FCS, 100 Units/ml penicillin, 100 μg/ml streptomycin and
100 μg/ml gentamycin (Sigma) for 2–4 days before
experiments. The present investigation was approved by
the institutional ethics committee. Handpicked islets were
then exposed to 5.6 or 11 mmol/l glucose with or without
the GLP1R agonist exendin-4 (10 nmol/l) for 24 h.
Immunohistochemistry After stimulation, human islets were
partially dispersed by trypsin treatment and cells were fixed
and incubated with primary rabbit antibodies for MAFA,
ISL1 transcription factor, LIM/homeodomain, (islet-1)
(ISL1) and PDX1 (dilutions 1:250) and mouse anti-insulin
(1:1,000, Sigma), followed by labelling with secondary
antibodies and staining with 10 μg/ml 4′,6-diamidino-2-
phenylindole. Images were acquired with a Zeiss Axiocam
Imaging System (Bioimaging Core Facility, Medical Fac-
ulty, Geneva University, Geneva, Switzerland).
Statistics Results are expressed as mean±SEM and statisti-
cal analyses were performed by unpaired Student’s t test.
Results
Establishment of stable INS-1 cell lines permitting inducible
expression of Mafa and DN-Mafa We established more
than ten clones positively expressing Mafa and DN-Mafa,
respectively, using parental INS-rbeta cells [20]. The
clones, designated as Mafa*22 and DN-Mafa*39, were
selected for the present study because they displayed robust
levels of Mafa or DN-Mafa mRNAs after doxycycline
induction and showed undetectable background expression
under non-induced conditions.
Characterisation of INS-1 clones producing MAFA and
DN-MAFA Immunofluorescence with an antibody against
the N-terminal epitope haemagglutinin tag illustrated that
nuclear-localised MAFA (Fig. 1a) and DN-MAFA (Fig. 1b)
proteins were induced in an all-or-none manner. Both
Mafa*22 (Fig. 1a) and DN-Mafa*39 cells (Fig. 1b) were
cultured with 500 ng/ml doxycycline for 24 h.
Western blotting (Fig. 2a) with an antibody against the C-
terminus of MAFA demonstrated that Mafa*22 cells
expressed the transgene-encoded protein in a doxycycline
dose-dependent manner. The protein levels of MAFA in cells
cultured for 24 h with 75, 150 and 500 ng/ml doxycycline
were approximately threefold, sixfold, and 15-fold higher
than the endogenous level (Fig. 2a). As expected, the same
MAFA antibody also recognised DN-MAFA, which was
induced about fivefold compared with endogenous wild-type
MAFA after 500 ng/ml doxycycline treatment for 24 h
(Fig. 2a). Most importantly, DN-Mafa*39 cells did not show
detectable expression of DN-MAFA protein under non-
induced conditions (Fig. 2a).
Fig. 2 MAFA binding to the insulin promoter was enhanced by
induction of MAFA and diminished by DN-MAFA. a Immunoblotting
with antibody against MAFA demonstrated the graded induction of
MAFA protein after induction with incremental doses of doxycycline.
DN-MAFA protein was induced by doxycycline in an all-or-none
manner (0 and 500 ng/ml doxycycline). Nuclear proteins were
extracted from Mafa*22 and DN-Mafa*39 cells induced for 24 h
with indicated concentrations of doxycycline. b EMSA with the
RIPE3b/C1 element of the insulin promoter demonstrated that MAFA
DNA-binding activity was incrementally increased by graded over-
production of MAFA (left) and nearly abolished by induction of DN-
MAFA (right). The antibody against the C-terminus of MAFA
supershifted both MAFA and DN-MAFA as expected. Nuclear
proteins were extracted from Mafa*22 and DN-Mafa*39 cells induced
for 24 h with the indicated concentrations of doxycycline. Two to four
independent experiments were performed with similar results
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EMSA with the RIPE3b/C1 element of the insulin
promoter demonstrated that doxycycline-induced MAFA
production increased its DNA-binding activity dose-depen-
dently (Fig. 2b). The intensity of retarded MAFA binding
complexes, performed with nuclear extracts from cells
cultured for 24 h with 75, 150, and 500 ng/ml doxycycline,
was estimated to be fivefold, 15- and 15-fold, respectively,
compared with that of endogenous MAFA (Fig. 2b). DN-
MAFA lacks the N-terminal transactivation domain, but
contains intact DNA-binding activity [3]. It therefore exerts
its dominant-negative function through competing with
endogenous MAFA for cognate DNA binding. Indeed,
induction of DN-MAFA almost completely abolished
MAFA DNA-binding activity (Fig. 2b). Again, no leakage
binding activity of DN-MAFA was observed under non-
induced conditions. The specificity of retarded binding
complexes of MAFA and DN-MAFA were confirmed by
the supershift experiments with MAFA antibody.
MAFA controls the expression of beta-cell-specific genes To
explore the gene expression patterns regulated by MAFA,
we performed quantitative northern blotting using total
RNAs extracted from Mafa*22 and DN-Mafa*39 cells
under induced and non-induced conditions. As shown in
Fig. 3a, graded overexpression of Mafa resulted in a
stepwise increase in levels of Pdx1 and Nkx6-1 mRNAs.
Overexpression of Mafa approximately threefold above the
endogenous level induced maximum expression of the
insulin gene and Glp1r (Fig. 3a). To rule out the possibility
that this observation was an artefact caused by super-
physiological overexpression of Mafa, we also investigated
the gene expression profile in Mafa*22 cells cultured with
increasing concentrations of glucose in the presence of
75 ng/ml doxycycline (Fig. 3b). Induction of Mafa by
three- to fourfold drastically increased the mRNA levels of
five beta-cell-specific genes including insulin, Glp1r, Pdx1,
Nkx6-1 and Pcsk1 [22, 27–32]. GLP1R mediates the
positive effects of GLP-1 on beta cell growth and insulin
secretion [28], whereas PCSK1 (PC-1/3) plays a dominant
role in processing of proinsulin [33]. In contrast, the
expression of Tcf1, Hnf4a, and Neurod1, which are
ubiquitously distributed in all islet endocrine cells [34,
35], was not induced by MAFA (Fig. 3b). Interestingly,
MAFA represents, to date, the most potent transcription
factor in the regulation of insulin gene expression and
possibly of other beta-cell-specific genes in our systematic
screening of INS-1 cell models. An increase in endogenous
insulin expression has never been observed in similar INS-1
cell lines expressing Pdx1 [20], Tcf1 [26] and Hnf4a [36],
as well as Neurod1 and paired-box gene 4 (Pax4)
(unpublished data, H. Wang and C. M. Wollheim).
Accordingly, induction of DN-MAFA led to a marked
reduction in the transcript levels of insulin, Glp1r, Pdx1,
Fig. 3 MAFA targets beta-cell-specific genes. The gene expression
pattern in these cells was quantitatively evaluated by northern blotting.
Total RNA samples (20 μg) were analysed by hybridising with the
indicated cDNA probes. The experiments were repeated twice with
similar results. a Mafa*22 cells were cultured in standard medium
(11.2 mmol/l glucose) with 0, 75, 150 or 500 ng/ml doxycycline for
24 h. Two independent experiments were blotted side by side to
demonstrate reproducibility. At 75, 150 and 500 ng/ml doxycycline,
Mafa was induced by 3.2-, 8.7- and 11.6-fold, respectively. This caused
a corresponding increase in the expression of the insulin gene (by 1.8-,
1.8- and 1.5-fold), Glp1r (by 2.4-, 2.2- and 2.3-fold), Pdx1 (3.1-, 4.7-,
and 4.8-fold) and Nkx6-1 (2.7-, 3.1-, and 4.2-fold). Data represent the
average of two experiments. b Mafa*22 cells were cultured with or
without 75 ng/ml doxycycline in 2.5 mmol/l glucose medium for 16 h,
and then incubated for a further 8 h at the indicated glucose
concentrations. The 3.4-fold induction of Mafa resulted in increased
expression of the insulin gene (by 1.9-fold), Glp1r (by 3.2-fold), Pdx1
(by 4.1-fold) and Nkx6-1 (by 2.3-fold). Data represent the average of
experiments at four glucose concentrations. c DN-Mafa*39 cells were
cultured with or without 500 ng/ml doxycycline in 2.5 mmol/l glucose
medium for 16 h, and then incubated for a further 8 h at the indicated
glucose concentrations. Induction of DN-Mafa led to decreased mRNA
levels of insulin (by 62%), Glp1r (by 74%), Pdx1 (by 91%), Nkx6-1 (by
31%) and Pcsk1 (by 52%). Data represent the average at the four
glucose concentrations
352 Diabetologia (2007) 50:348–358
Nkx6-1 and Pcsk1, whereas the expression of Tcf1 and
Hnf4a was unaltered (Fig. 3c). However, Neurod1 expres-
sion was suppressed by DN-MAFA (Fig. 3c).
We and others have previously shown that PDX1 and
NKX6-1 suppress glucagon expression, causing a shift
from an alpha to a beta phenotype [20, 31]. We therefore
examined whether MAFA has a similar function. Unex-
pectedly, induction of MAFA did not inhibit the expression
of glucagon, as demonstrated by northern blotting after
prolonged film exposure (Electronic supplementary materi-
al [ESM] Fig. 1). More intriguingly, induction of DN-
MAFA diminished levels of glucagon mRNA (ESM
Fig. 1), an effect opposite to that observed in response to
suppression of PDX1 or NKX6-1 activity in INS-1 cells.
Therefore, the effects of MAFA cannot be simply explained
as functioning through PDX1 or NKX6-1.
MAFA regulates the expression of genes implicated in
glucose metabolism We investigated further the effects of
MAFA on other beta-cell-specific genes involved in glucose
metabolism. Using quantitative northern blotting analysis we
found that overexpression ofMafa robustly up-regulated the
expression of two beta-cell-restricted genes, namely Slc2a2
and Pc (Fig. 4a,b). In addition, dominant-negative suppres-
sion of Mafa drastically downregulated transcript levels of
these two genes (Fig. 4c). SLC2A2 is the major glucose
transporter expressed in rodent beta cells [37], while
pyruvate carboxylase participates in the regulation of
metabolism–secretion coupling in beta cells [38, 39].
Although Gck is expressed in both islet alpha and beta
cells, it has been shown to confer beta cell glucose-sensing
[25, 40]. The mRNA levels of Gck were elevated by MAFA
and reduced by DN-MAFA (Fig. 4). Such effects seem to
be unique to MAFA, since Gck expression remained
constant in our INS-1 cells permitting either induction or
dominant-negative suppression of other pancreatic tran-
scription factors, such as PDX1 [20], TCF1 [26], and
HNF4α [36], as well as NEUROD1 or PAX4 (unpublished
data, H. Wang and C. M. Wollheim).
The expression of other genes encoding proteins
implicated in metabolism–secretion coupling, such as
UCP2, TFAM, HADH2, and acyl-CoA oxidase [41–43],
was not regulated by manipulation of MAFA function in
INS-1 cells (Fig. 4). UCP2 and TFAM modulate, respec-
tively, the membrane potential and biogenesis of mitochon-
dria, whereas HADH2 and acyl-CoA oxidase are involved
in fatty acid metabolism.
MAFA regulates glucose-stimulated insulin secretion The
effects of MAFA on the expression of Gck and Pc as well
as Slc2a2 suggest that MAFA could be implicated in the
regulation of metabolism–secretion coupling in beta cells.
We therefore examined the impact of induction or domi-
nant-negative suppression of MAFA on insulin secretion in
INS-1 cells. As shown in Fig. 5a, overexpression of Mafa
caused a shift to the left in insulin secretion in response to
glucose. The MAFA-induced increase in Gck expression
(Fig. 4a,b) should, at least in part, explain the left shift in
glucose responsiveness, because similar results have been
Fig. 4 MAFA targets genes essential for metabolism–secretion
coupling. Total RNA samples (20 μg) were analysed by hybridising
with indicated cDNA probes. The experiments were repeated twice
with similar results. a Mafa*22 cells were cultured as described in
Fig. 3a. Two separate experiments were blotted side by side to
demonstrate consistency. Mafa was induced 3.4-, 8.3- and 10.2-fold
by 75, 150 and 500 ng/ml doxycycline, respectively. This resulted in
corresponding increases in the mRNA levels of Pc (by 4.4-, 4.8- and
4.5-fold), Slc2a2 (by 3.1-, 3.7- and 3.3-fold), and Gck (by 2.2-, 2.1-
and 1.8-fold). Data represent the average of two experiments.
b Mafa*22 cells were cultured as described in Fig. 3b. A 3.6-fold
induction of Mafa caused increased expression of Pc, Slc2a2 and Gck
by 4.3-, 2.4- and 1.9-fold, respectively. Data represent the average at
four glucose concentrations. c DN-Mafa*39 cells were cultured as
described in Fig. 3c. The gene expression pattern in these cells was
quantitatively evaluated by northern blotting. Equilibration with
2.5 mmol/l glucose is necessary to observe glucose-responsive gene
expression, such as Slc2a2. Induction of DN-MAFA led to decreased
expression of Pc, Slc2a2 and Gck by 62, 46 and 37%, respectively.
Data represent the average at the four glucose concentrations. WT,
wild-type
Diabetologia (2007) 50:348–358 353
obtained in INS-1 cells overexpressing Gck [25], the rate-
limiting enzyme for beta cell glucose metabolism. In
contrast, dominant-negative suppression of MAFA func-
tion led to blunted glucose-induced insulin secretion,
whereas insulin release elicited by KCl depolarisation
remained constant (Fig. 5b). These results suggest that
MAFA regulates metabolism–secretion coupling in steps
upstream of exocytosis. INS-1 cells represent a unique
model to assess the implications of pyruvate carboxylase
in metabolism-secretion coupling, because these insuli-
noma cells produce low levels of monocarboxylate
transporter, but sufficient to use pyruvate as secretogue
[44, 45], in contrast to native islet beta cells. We therefore
evaluated the consequences of DN-MAFA on pyruvate-
stimulated insulin secretion in INS-1 cells. As demon-
strated in Fig. 5b, induction of DN-MAFA also impaired
insulin secretion in response to pyruvate, which could be
explained by markedly reduced pyruvate carboxylase
production (Fig. 4c). The insulin secretion data were
expressed as percentage of cellular insulin, because
induction of MAFA and DN-MAFA resulted in a 23%
increase and 27% decrease, respectively, in the cellular
insulin content.
MAFA is expressed specifically in beta cells of human
islets. To characterise MAFA production in adult human
islets, we performed immunofluorescence staining with
antibodies against ISL1, MAFA, PDX1 and insulin. As
shown in Fig. 6a, MAFA is specifically localised in nuclei
of insulin-positive cells, whereas ISL1 is stained in both
beta and non-beta cells. PDX1 is also almost exclusively
localised in nuclei of beta cells (Fig. 6a). In addition,
subcellular distribution of MAFA was not strikingly
different in human islets cultured for 24 h in 5 and
11.2 mmol/l glucose, respectively (Fig. 6b). The negative
effects of the GLP1R agonist, exendin-4, were pronounced
(Fig. 6b). Since immunostaining is semi-quantitative, small
changes in protein levels may not be obvious. We therefore
performed EMSA to evaluate the glucose-responsiveness of
DNA binding by MAFA.
Glucose regulates MAFA DNA-binding activity in rat islets
Findings on glucose-regulation of MAFA have been very
confusing [5, 14, 15, 46]. Zhao and colleagues [46]
reported that both MAFA protein levels and its binding to
the RIPE3b/C1 element are markedly increased in rat islets
cultured for 24 h with 16.7 mmol/l glucose, in comparison
with control islets treated with 2.8 mmol/l glucose. Similar
glucose-induced MAFA DNA-binding activity was demon-
strated in insulinoma MIN6 and β-TC6 cells [5]. In
contrast, reduced MAFA DNA-binding activity and MAFA
levels have been shown in INS-1 cells cultured with
16.7 mmol/l glucose for 48 h [17] and in HIT-T15 cells
treated chronically with 11.1 mmol/l glucose [16]. To
clarify this, we performed EMSA with nuclear extracts
from rat islets cultured with 2.5, 5, 15 and 30 mmol/l glucose
for 48 h. As shown in Fig. 7, MAFA DNA binding is
regulated by glucose in a bell-shaped manner. The DNA-
binding activity was incrementally increased in the range
2.5–15 mmol/l glucose, but reduced at 30 mmol/l glucose.
These results not only support the notion that glucose
enhances MAFA DNA binding [5, 46], but are also in
agreement with the previous finding that glucotoxicity
diminishes the DNA-binding activity [14, 16, 17]. The
discrepancy between the studies in rat islets and insulinoma
cells could be related to decreased sensitivity of the former to
high glucose.
Fig. 5 MAFA regulates nutrient-stimulated insulin secretion.
aMafa*22 cells were cultured in standard medium (11.2 mmol/l glucose)
with (dark bars) or without (open bars) 75 ng/ml doxycycline (Dox) for
19 h, and then equilibrated in 2.5 mmol/l glucose medium for a further
5 h. Insulin release from Mafa*22 cells in KRBH buffer containing the
indicated concentrations of glucose was determined by radio-immuno-
assay and expressed as percentage of cellular insulin content. Cellular
insulin content was increased by 23% (−Dox: 2.16±0.23 μg/mg protein;
+Dox: 2.65±0.25 μg/mg protein, n=6, p<0.01) after MAFA induction.
b DN-Mafa*39 cells were cultured in standard medium (11.2 mmol/l
glucose) with (dark bars) or without (open bars) 500 ng/ml doxycycline
for 19 h, and then equilibrated in 2.5 mmol/l glucose medium for a
further 5 h. Induction of DN-MAFA resulted in defective insulin release
induced by 24 mmol/l glucose, 5 mmol/l pyruvate, and 20 mmol/l KCl.
Insulin secretion fromDN-Mafa*39 cells stimulated by 24mmol/l glucose,
5 mmol/l pyruvate, and 20 mmol/l KCl was measured in KRBH
containing 2.5 mmol/l glucose (Basal) and is expressed as percentage
of cellular insulin content. Cellular insulin content was reduced by 27%
(−Dox: 2.245±0.22; +Dox: 1.64±0.20 μg/mg protein, n=6, p<0.005).
Data represent mean±SEM of six independent experiments. *p<0.05,
**p<0.001
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Discussion
Using two INS-1 stable cell lines permitting inducible
overexpression or dominant-negative suppression of
MAFA, we assessed the effects of MAFA on insulin
secretion. Overproduction of MAFA caused a left shift of
insulin secretion in response to glucose, whereas induction
of DN-MAFA blunted nutrient-stimulated insulin release.
This was not due to alterations in insulin content, since the
data were expressed as percentage of cellular insulin.
Recently, Zhang and colleagues [47] reported that mice
deficient in MAFA developed diabetes due to impaired
insulin secretion. However, the authors did not define the
molecular targets responsible for the phenotype. We have
defined the target genes of MAFA through quantitative
gene expression profiling of our novel INS-1 cell lines
Fig. 6 MAFA is localised
specifically in beta cells of
human islets. a Immunofluores-
cent detection of the islet
transcription factors ISL1, IPF1
or MAFA (green), and insulin
(red), as well as 4′,6-diamidino-
2-phenylindole (DAPI) nuclei
staining (blue) in dispersed
human islet cells cultured at
11.2 mmol/l glucose for 24 h.
Similar to IPF1, MAFA is
exclusively detected in the
nuclei of insulin-positive cells.
b Immunocytochemical
detection of MAFA (green)
and beta cells (insulin in red)
was performed 24 h after
incubation with the indicated
concentrations of glucose (Glc)
with or without the GLP1R
agonist exendin-4 (ex-4,
10 nmol/l). The merge image of
the MAFA- and insulin-
producing beta cells is shown
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under induced and non-induced conditions. The results
demonstrate that MAFA is not only a key activator of
insulin transcription, but also a master regulator of many
beta cell genes implicated in maintaining beta cell pheno-
type, metabolism–secretion coupling, proinsulin processing
and GLP1R signalling.
Overexpression of Mafa alone is sufficient to raise
endogenous insulin mRNA levels. This is unique to MAFA,
because induction of PDX1 [20] or NEUROD1, either
separately or combined in the similar INS-1 cell system
(unpublished data, H. Wang and C. B. Wollheim), did not
reproduce the effects of MAFA. Similarly, other key beta
cell transcription factors such as TCF1 and HNF4α, as well
as PAX4, do not show such potency in our systematic series
of INS-1 cell models [26, 36]. Transduction of MAFA has
been shown to increase endogenous insulin transcript
expression in rat islets [46]. We therefore propose that
MAFA could be a potent and target transcription factor
employed for beta cell generation either through in vivo gene
therapy or in vitro differentiation of stem/progenitor cells.
Accordingly, dominant-negative suppression of MAFA
function decreased insulin production as revealed by
mRNA and protein contents. We have also identified the
beta-cell-enriched PCSK1and GLP1R as two novel targets
of MAFA. DN-MAFA drastically suppressed the expression
of Pcsk1 and Glp1r, whereas induction of MAFA enhanced
their transcript levels. PCSK1 is required for insulin
maturation [33], whereas GLP1R is necessary for GLP1-
mediated beta cell growth and insulin secretion [28]. A
similar reduction of PCSK1 and GLP1R levels has also
been observed in our INS-1 cells expressing DN-Pdx1,
which causes defective proinsulin processing and GLP1R
signalling [21]. MAFA has been previously reported to bind
the Pdx1 promoter [48]. Indeed, we found that PDX1 is
robustly up- or downregulated following induction and
suppression of MAFA function. Decreased expression of
Pdx1 has also been demonstrated in MAFA-deficient islets
[47]. We therefore postulate that MAFA regulates expres-
sion of Pcsk1 and Glp1r, at least in part by acting through
PDX1.
In addition, we have also identified two other common
target genes of MAFA and PDX1: Slc2a2 and Nkx6-1. Like
PDX1, MAFA also controls the expression of these two
beta-cell-restricted genes. Decreased levels of SLC2A2
have also been reported in the islets of Mafa-null mice
[47]. However, this does not explain the impaired insulin
secretion [47]. As the capacity of this hexose transporter is
much greater than the activity of GCK and other glycolytic
enzymes, this decrease would not affect glucose metabo-
lism [37]. To delineate the molecular targets responsible for
the regulatory effects of MAFA on insulin secretion, we
evaluated the expression patterns of genes involved in
metabolism–secretion coupling with or without induction of
MAFA or DN-MAFA. The beta-cell-enriched PC has been
identified as another novel target of MAFA in the present
study. PC plays an essential role in metabolism–secretion
coupling in both native beta cells and insulinoma cells [38,
39]. Approximately 50% of glucose-derived pyruvate
enters mitochondrial metabolism via carboxylation cata-
lysed by PC, while the remainder is converted into acetyl
CoA by the pyruvate dehydrogenase complex [38]. This
provides anaplerotic input into the tricarboxylic acid cycle
[49]. INS-1 cells, which express low levels of monocarbox-
ylate transporter that are nonetheless sufficient to take up
pyruvate, provide a suitable model to assess the impact of
decreased PC production on insulin secretion. Induction of
DN-MAFA not only impaired glucose-stimulated but also
pyruvate-induced insulin release. As pyruvate is metabol-
ised exclusively by the mitochondria, the downregulation of
PC certainly contributes, together with GCK, to the insulin
secretory defect. On the other hand, the MAFA-evoked
overproduction of PC may partially contribute to the left
shift of insulin secretion in response to glucose. However,
the beta cell glucose-sensor, GCK, should be the major
player, since a similar left shift of insulin secretory
response has been documented in INS-1 cells overproduc-
ing GCK [25]. At variance with Mafa-deficient mice, we
found that mRNA levels of Gck were regulated positively
by MAFA and negatively by DN-MAFA. This is also
unique to MAFA because Gck expression remains constant
in our INS-1 stable cell lines allowing induction or
suppression of other pancreatic transcription factors, in-
cluding PDX1 [20], TCF1 [26], HNF4α [36], NEUROD1
Fig. 7 Bell-shaped DNA-binding of MAFA in response to glucose
was demonstrated in rat islets. EMSA was performed using the
RIPE3b/C1 element of the insulin promoter. Nuclear proteins were
extracted from rat islets cultured with 2.5, 5, 15 and 30 mmol/l glucose
for 48 h. DNA-binding activity was increased by 3.3±0.7, 12.1±2.5,
and 2.2±0.4-fold (n=3) at 5, 15, and 30 mmol/l glucose concen-
trations, respectively. Data were calculated by scanning three
independent EMSA experiments using rat islets from two separate
isolations
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or PAX4 (unpublished data, H. Wang and C. B. Wollheim).
The reason for the apparent difference in GCK regulation in
Mafa-mutant mice and INS-1 cells is not clear. Moreover,
K+-induced insulin secretion was inhibited in islets from
Mafa−/− mice but not affected in INS-1 cells with
suppressed MAFA function. This could be due to effects
on L-type voltage-gated Ca2+channels in native beta cells.
INS-1 cells express a broader spectrum of such Ca2+channels
than native beta cells [50], which may explain the preserved
insulin secretion following membrane depolarisation.
Another intriguing result with MAFA is that it does not
promote the alpha to beta phenotype shift observed with
PDX1 and NKX6-1 [20, 31], although our data suggest that
MAFA regulates their production. We have previously
shown that PDX1 suppresses glucagon production and
regulates the alpha/beta phenotype shift in INS-1 cells [20].
A recent elegant study in INS-1-derived cells suggests that
PDX1 acts through NKX6-1 [31]. Therefore, the effects of
MAFA on beta-cell-specific gene expression cannot be
explained simply by an action on PDX1. Another argument
supporting this notion is that overexpression of Pdx1 does
not potentiate glucose-stimulated insulin secretion [21].
Furthermore, in agreement with findings in Mafa-null mice
[46], induction of DN-MAFA diminished the expression of
Neurod1 in INS-1 cells, although MAFA induction did not
affect its transcript levels.
We also demonstrated that MAFA is specifically expressed
in the beta cells of human islets and that its subcellular
distribution is not clearly regulated by physiological concen-
trations of glucose. However, the DNA-binding activity of
MAFA is indeed regulated in a bell-shape manner that is
dependent on glucose concentration. We therefore clarified
the apparent controversies in the literature regarding the
glucose responsiveness of MAFA DNA binding [5, 16, 17,
46]. To summarise data from the present study and previous
reports, we suggest that glucose inducesMAFADNA-binding
activity at physiological concentrations, but suppresses the
binding at both sub- and supra-physiological levels.
In conclusion, we employed an inducible INS-1 cell
system, which allows direct assessment of MAFA target
genes. We have demonstrated that MAFA controls many
beta-cell-specific genes, including insulin, Slc2a2, Pdx1,
Nkx6-1, Glp1r, Pcsk1 and Pc. PC in combination with
GCK may represent the molecular targets responsible for
the regulatory effects of MAFA on metabolism–secretion
coupling. Furthermore, MAFA regulates expression of
genes essential for insulin transcription and processing, as
well as for GLP1R signalling. Therefore, we propose that
MAFA is a candidate gene for diabetes and a target gene for
restoring beta cell function in type 2 diabetes. In addition, it
is also a potential target for treatment of type 1 diabetes
through MAFA-mediated in vitro beta cell generation from
progenitor/stem cells or in vivo gene therapy.
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